<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160308026973N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-08</date_registration>
      <primary_sponsor>Babol University of Medical Sciences</primary_sponsor>
      <public_title>Assesment the effect of Domperidone in the treatment of Functional Abdominal Pain in children</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effectiveness of Domperidon with Placebo in the treatment of Functional Abdominal Pain in children</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52646</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The research-aware nurse divided the samples into 2 categories using Block randomized. Both the physician and the patient will be blind to the grouping of patients (Double blind), Blinding description: After the diagnosis of FAP was given to the patients by the Pediatric Gastroenterologist and the initial questionnaires were completed by the Pediatric assistant under the supervision of the Pediatric Gastroenterologist, the patient was referred to a knowledgeable nurse for research. She will place the samples in 2 categories using Block randomized .</study_design>
      <phase>3</phase>
      <hc_freetext>Functional Abdominal Pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Domperidone tablets 0.25mg / kg TDS up to 8 weeks (Hakim Pharmaceutical Company). Intervention 2: Control group: Placebo which is completely similar to Domperidone in terms of shape, appearance and color ( Faculty of Pharmacy, Sari University of Medical Sciences).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data including primary (before treatment) and secondary (end of treatment) questionnaires including patients' demographic information, pain frequency, pain intensity and duration of pain can be shared after the individuals not being identified.

When:
Documents are available forever after the results are published.

To whom:
The documentation will be accessible to everyone.

Conditions:
It is possible to use the documents in other scientific articles and to obtain new results in different contexts while submitting a written request and agreeing to be responsible for the study response.

Where to obtain:
It is possible to receive documents from the Research Center of Babol University of Medical Sciences (Babol University of Medical Sciences located in Ganj Afrooz St.) or by correspondence with the person in charge of public accountability of the study via email (n.tavackoli.h@gmail.com).

How to obtain:
It is possible by submitting a request in person or by e-mail through the said addresses.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Negin Tavackoli Haghighi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 19, Amirkola Children’s Hospital, Amirkola</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4731741151</zip>
        <telephone>+98 11 3235 4951</telephone>
        <email>N.tavackoli.h@gmail.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sanaz Mehrabani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 19, Amirkola Children’s Hospital, Amirkola</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4731741151</zip>
        <telephone>+98 11 3235 4951</telephone>
        <email>mehrabanisanaz@yahoo.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>5-14 years old children referred to Amirkola Children's Hospital with diagnosis of functional abdominal pain (FAP)</inclusion_criteria>
      <agemin>5 years</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Existence of chronic disease
Taking other medications such as antibiotice and probiotic during the month before the start of the project
The presence of Abdominal pain's  red flags
Constipation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K59.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Functional intestinal disorder, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Domperidone tablets 0.25mg / kg TDS up to 8 weeks (Hakim Pharmaceutical Company)</i_keyword>
      <i_keyword>Control group: Placebo which is completely similar to Domperidone in terms of shape, appearance and color ( Faculty of Pharmacy, Sari University of Medical Sciences)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Change at least 50% of the frequency of pain. Timepoint: At the beginning of the study and after two months of medication (end of the study). Method of measurement: Based on the questionnaire of reducing the frequency of pain, pain intensity and duration of pain (assessment of pain intensity based on face scale questionnaires).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Abdominal pain intensity based on Wong-Baker FACES Pain Rating Scale  questionnaire. Timepoint: At the beginning of the study (before the intervention) and after two months of medication (end of the study). Method of measurement: Wong-Baker FACES Pain Rating Scale  questionnaire.</sec_outcome>
      <sec_outcome>Duration of pain. Timepoint: At the beginning of the study (before the intervention) and after two months of medication (end of the study). Method of measurement: Attached questionnaire at the end of the proposal (based on patient statements).</sec_outcome>
      <sec_outcome>Pain frequency (number of pain days per month). Timepoint: At the beginning of the study (before the intervention) and after two months of medication (end of the study). Method of measurement: Attached questionnaire at the end of the proposal (based on patient statements).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-10</approval_date>
        <contact_name>Ethics committee of Babol University of Medical Sciences</contact_name>
        <contact_address>No 19, Amirkola Children’s Hospital, Amirkola, Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
